Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study to evaluate the QT/QTc of RADICAVA (edaravone) in healthy subjects

Trial Profile

A clinical study to evaluate the QT/QTc of RADICAVA (edaravone) in healthy subjects

Planning
Phase of Trial: Phase IV

Latest Information Update: 28 Aug 2018

At a glance

  • Drugs Edaravone (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Aug 2018 New trial record
    • 08 Aug 2018 According to a Mitsubishi Tanabe Pharma America media release, the company is working with the US FDA to conduct a post-marketing commitment study to understand of the effect of more frequent and higher doses of RADICAVA on ALS. This post-marketing commitment study includes 1) Pharmacokinetics study in patients with severe hepatic impairment (298980) 2) QT/QTc evaluation in healthy subjects (299043). 3)Clinical study with more frequent and higher doses of RADICAVA for at least 24 weeks (299046).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top